New Therapies Shed Light on RAS-Mutated Pancreatic Cancer Management

Commentary
Video

Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.

In a conversation with CancerNetwork® ahead of his presentation at the 15th Annual Ruesch Center Symposium, Shubham Pant, MD, MBBS, discussed what he hoped colleagues would take away from his session focused on the development of targeted therapies for patients with RAS-mutated pancreatic cancer.

Pant, a professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center, and gastrointestinal cancer editorial advisory board member for ONCOLOGY, contextualized his presentation by highlighting how the RAS mutation was previously considered an “undruggable” target. With the development of novel therapeutic strategies such as pan-RAS inhibitors, Pant stated that the field is now experiencing an “exciting” time.

Based on the ongoing initiatives he will describe in his presentation; Pant ultimately looks for his colleagues to take away a feeling of hope for the future of the field.

Transcript:

I’m excited about the [Ruesch] Symposium this year. About a decade back, we did not have anything to target RAS [mutations], and RAS was called undruggable. However, we first had the KRAS G12C inhibitors, which were mostly in lung and colorectal cancer. Now we have other inhibitors called pan-RAS inhibitors that can target pancreatic cancer. [Approximately] 90% of pancreatic cancer is KRAS-mutated. It’s an exciting time in this field.

What I hope my colleagues take away is that there’s a lot of hope in the future. Pancreatic cancer, normally, has been a tough and devastating disease. Survival has not budged a lot; it has done a bit, but not a lot, only in single digits in the last decades. I truly think this is the moment in which we’re getting newer therapeutics, which can have an impact on our patients’ lives. I hope they take away some hope from this presentation.

Reference

Pant S. Targeting the RAS mutation in pancreatic cancer. Presented at the 15th Annual Ruesch Center Symposium; November 21-23, 2024; Washington, DC.

Recent Videos
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content